CliffBio
small molecule

DARIFENACIN HYDROBROMIDE

DARIFENACIN HYDROBROMIDE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameDARIFENACIN HYDROBROMIDE
Active ingredientDARIFENACIN HYDROBROMIDE
StrengthEQ 7.5MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2016
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DARIFENACIN HYDROBROMIDE patent cliff — loss of exclusivity — | CliffBio